Market Overview

Immunogen Shares Charge Higher Following News of Deal with Lilly for TAP Technology

Share:
Related IMGN
ImmunoGen Announces Recent Product Program Advancements and Anticipated 2016 Events in Advance of J.P. Morgan Healthcare Conference
Buy ImmunoGen On Transformational Products, Jefferies Says
ImmunoGen to evaluate combo of lead product candidate and Merck's Keytruda in ovarian cancer (Seeking Alpha)
Related LLY
Credit Suisse Global Focus List Update: Toyota Out, Agnico Eagle In
Earnings Recap For January 28
Top Funds Heart Edwards Lifesciences, Bump Lilly (Investor's Business Daily)

Immunogen (NASDSAQ: IMGN) shares are rallying in early-afternoon trade Wednesday following a Form 8-K just filed with the SEC.

From the filing: "On August 26, 2013, ImmunoGen, Inc. (referred to as “we,” “us” or the “Company”) entered into a license agreement with Eli Lilly and Company (NYSE: LLY) (“Lilly”) granting Lilly rights to use our maytansinoid-based Targeted Antibody Payload (TAP) technology to develop and commercialize products directed to a specific antigen target on an exclusive basis. This license was granted pursuant to the terms of an existing Multi-Target Agreement entered into by the Company and Lilly in 2011. In accordance with the terms of the Multi-Target Agreement, execution of the license agreement entitles us to receive development, regulatory and sales milestone payments potentially totaling $200.5 million, as well as royalties on the commercial sales of any resultant products."

Posted-In: News Movers

 

Related Articles (LLY)

View Comments and Join the Discussion!

Get Benzinga's Newsletters